AHA Scientific Sessions 2026 Abstract
Updated guidelines favor cholesterol drugs for more US adults
The 2026 framework identified 15.9 million more untreated US adults for consideration of cholesterol-lowering medication than the 2018 framework.The 2026 framework identified 15.9 million more untreated US adults for consideration of cholesterol-lowering medication than the 2018 framework.
Cross-sectional · 6,118 peopleIndustry & policy
Who was studied6,118 U.S. adults aged 40-75 years, against adults under the 2018 framework
What changedThe number of untreated adults considered for cholesterol-lowering medication rose by 15.9 million under the updated versus older guideline
The catchTreatment classifications excluded refinement using coronary artery calcium or additional risk factors